Harnessing the Human Microbiome for Next-Generation Drug Discovery

Abstract

The human microbiome, a complex ecosystem of trillions of microorganisms, is now recognized as a virtual endocrine organ that profoundly influences host physiology. Beyond its role in metabolism and immunity, the microbiome produces a vast repertoire of small molecules that can mimic, modulate, or interfere with host signaling pathways. These bacterially-derived metabolites represent an untapped reservoir of novel therapeutic agents. This review explores the paradigm of mining the human microbiome for drug discovery. We outline the methodological pipeline for identifying candidate molecules, from multi-omics correlation studies to functional validation in gnotobiotic models. We highlight key examples of microbiome-derived modulators of host physiology, including metabolites targeting G protein-coupled receptors (GPCRs), nuclear receptors, and epigenetic machinery. Finally, we discuss the challenges and future directions in translating these findings into viable therapeutics, emphasising the need for advanced culturing techniques, synthetic biology, and robust clinical validation. Harnessing this microbial "dark matter" holds immense promise for treating a wide range of diseases, from metabolic disorders to neurological conditions.